The peroxisome proliferator-activated receptor ␥ (PPAR␥) is a target for treatment of type II diabetes and other conditions. PPAR␥ full agonists, such as thiazolidinediones (TZDs), are effective insulin sensitizers and anti-inflammatory agents, but their use is limited by adverse side effects. Luteolin is a flavonoid with anti-inflammatory actions that binds PPAR␥ but, unlike TZDs, does not promote adipocyte differentiation. However, previous reports suggested variously that luteolin is a PPAR␥ agonist or an antagonist. We show that luteolin exhibits weak partial agonist/ antagonist activity in transfections, inhibits several PPAR␥ target genes in 3T3-L1 cells (LPL, ORL1, and CEBP␣) and PPAR␥dependent adipogenesis, but activates GLUT4 to a similar degree as rosiglitazone, implying gene-specific partial agonism. The crystal structure of the PPAR␥ ligand-binding domain (LBD) reveals that luteolin occupies a buried ligand-binding pocket (LBP) but binds an inactive PPAR␥ LBD conformer and occupies a space near the ␤-sheet region far from the activation helix (H12), consistent with partial agonist/antagonist actions. A single myristic acid molecule simultaneously binds the LBP, suggesting that luteolin may cooperate with other ligands to bind PPAR␥, and molecular dynamics simulations show that luteolin and myristic acid cooperate to stabilize the ⍀-loop among H2Ј, H3, and the ␤-sheet region. It is noteworthy that luteolin strongly suppresses hypertonicity-induced release of the pro-inflammatory interleukin-8 from human corneal epithelial cells and reverses reductions in transepithelial electrical resistance. This effect is PPAR␥-dependent. We propose that activities of luteolin are related to its singular binding mode, that anti-inflammatory activity does not require H12 stabilization, and that our structure can be useful in developing safe selective PPAR␥ modulators. This work was supported by Fundaçã o de Amparo a Pesquisa do Estado de Sã o Paulo (FAPESP) [Grant 2007/58443-4 and 2010/08680-2] and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Introduction
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors of the nuclear receptor family. The three PPAR subtypes (PPAR␣, PPAR␤, and PPAR␥) have different ligand specificity and tissue distribu-tion (Berger and Moller, 2002) . PPAR␥ is highly expressed in adipose tissue, macrophages, and cells of the vasculature (Tontonoz et al., 1994; Ricote et al., 1998) , plays essential roles in adipogenesis and glucose and lipid homeostasis (Auwerx, 1999; Lehrke and Lazar, 2005) , and exhibits antiinflammatory actions (Ricote and Glass, 2007) . PPAR␥ agonists such as the thiazolidinediones (TZDs) are efficient and clinically useful insulin sensitizers and are under investigation for the treatment of inflammation with potential applications in atherosclerosis (Koshiyama et al., 2001) , inflammatory colitis (Lewis et al., 2001) , arthritis (Giaginis et al., 2009) , and bowel disease (Borniquel et al., 2010) . PPAR may also be a useful target in ocular conditions. For example, dry-eye disease can result in tears with increased osmolarity, which can lead to breaches of the tight junctional barrier property of the corneal epithelium, resulting in an innate immune response, triggered by IL-8 release by corneal epithelium and the underlying stroma, and reductions in transepithelial electrical resistance (TEER) (Luo et al., 2005; Li et al., 2006) . PPAR␥ activation by endogenous metabolites formed in response to severe corneal injury in mice improves the wound-healing response to injury and reduces inflammation and fibrosis (Saika et al., 2007) .
Like other nuclear receptors, PPAR␥ consists of three domains: the N-terminal domain, the DNA-binding domain, and the ligand-binding domain (LBD) . The ability of PPAR␥ to promote or suppress the transcription of responsive genes depends on interaction of its LBD with ligands that stabilize receptor conformation. Full agonists, such as the TZDs, efficiently stabilize C-terminal H12, part of a coactivator binding cleft (activation function 2), allowing efficient recruitment of transcriptional coactivators (Berger and Moller, 2002) . The PPAR␥ ligand-binding pocket (LBP) is a large Y-shaped hydrophobic cavity (Nolte et al., 1998) with a volume almost twice that of LBPs of other nuclear receptors (Zoete et al., 2007) that can accommodate compounds such as fatty acids, arachidonic acid metabolites , antidiabetes drugs , and nonsteroidal antiinflammatory drugs (Lehmann et al., 1997) with different binding modes (Itoh et al., 2008) .
Although TZDs are efficient insulin sensitizers, their use is associated with increased fat mass (Larsen et al., 2003) , renal fluid retention, and more severe cardiovascular events (Mudaliar et al., 2003; Nissen and Wolski, 2007) . Thus, effort has been directed toward developing efficacious selective PPAR␥ modulators (SPPAR␥Ms) that improve insulin sensitivity and combat inflammation without inducing other harmful effects Higgins and Depaoli, 2010) . Partial agonists that occupy positions within the LBP near the ␤-sheets enhance insulin sensitivity without harmful side effects by inhibiting PPAR␥ LBD phosphorylation by the proinflammatory kinase cyclin-dependent kinase 5 (Choi et al., 2010; Choi et al., 2011) . Thus, alternate PPAR␥ ligand binding modes may be associated with altered, and potentially useful, spectrums of action relative to full agonists.
The flavonoids, naturally occurring plant polyphenols, display a remarkable array of biochemical and pharmacological actions (Havsteen, 2002) . Among them, luteolin (3Ј,4Ј,5,7tetrahydroxyflavone), present in celery, green pepper, perilla leaf, and chamomile tea, is a PPAR␥ ligand with antioxidant and anti-inflammatory properties (Xagorari et al., 2001) . Different studies, however, have suggested that luteolin can function either as a PPAR␥ agonist [enhances expression of PPAR␥-dependent genes in adipocytes (Ding et al., 2010) ] or a PPAR␥ antagonist [inhibits adipogenesis and PPAR␥-dependent gene expression in other contexts (Mueller et al., 2008; Park et al., 2009) ]. The fact that the mode of luteolin action is unclear prompted us to determine the mechanism of luteolin interaction with PPAR␥ and the biological relevance of such an effect in inflammatory response in human corneal epithelial cells (HCECs).
Here, we show that luteolin is a PPAR␥ partial agonist, explaining discrepancies in previous reports about its actions, and combined use of X-ray crystallography and molecular dynamics studies revealed a unique binding mode in which it binds to an inactive PPAR␥ LBD conformer in a position within the LBP that lies near the ␤-sheet region of the LBP. The luteolin binding mode permits the simultaneous presence of a long-chain fatty acid in the pocket, and simulations suggest that both ligands cooperate to stabilize the LBD in a different manner from full agonists. In hypertonicity-stressed HCECs, luteolin selectively suppressed release of a chemoattractant, IL-8, and reversed reductions in TEER, suggesting that this unique binding mode is associated with useful anti-inflammatory activities in cornea.
Materials and Methods
Cell Transactivation Assays. Plasmids used were pGRE-LUC (GAL4-responsive element, firefly luciferase reporter vector), the PPAR␥ LBD-GAL4 inserted in pBIND plasmid (Promega, Madison, WI), and the pRL-TK, which contains Renilla reniformis luciferase (Dual-Luciferase Report Assay system; Promega) and was used as transfection control. HepG2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 2 mM glutamine, 50 units/ml penicillin, and 50 mg/ml streptomycin under a 95% air/5% CO 2 atmosphere at 37°C. For transfection, cells were trypsinized, resuspended in DMEM, plated in 24-well plates (density of 1.2 ϫ 10 5 cells/well), and incubated with 50 ng of pGRE-LUC, 100 ng of PPAR␥ LBD-GAL4 vector, and 1 ng of pRL-TK, which were incubated with FuGENE (Roche, Indianapolis, IN) at a ratio of 1 g of DNA to 3 l of FuGENE at room temperature for 20 min before addition to cells. PPAR␥ ligands [rosiglitazone (as a control) and luteolin] were added to culture medium 24 h later and incubated with the cells overnight. The cell monolayer was washed with phosphate-buffered saline and harvested with lysis buffer (Dual-Luciferase Report Assay system; Promega) according to the manufacturer's instructions. Luciferase activity was determined using the Luciferase Assay System (Promega) and measured in a Safire 2 luminescent counter (Tecan US, Durham, NC). The R. reniformis luciferase activity was measured using the same cell lysate and used as an internal control. The EC 50 value was calculated using a sigmoidal dose-response function from plots of the relationship between luminescence and luteolin concentrations (10 Ϫ 9 to 10 Ϫ5 M), considering the following function: Y ϭ Bottom ϩ (Top Ϫ Bottom)/(1 ϩ 10 (LogEC50 Ϫ X) ), where X is the logarithm of concentration and Y is the response. These analyses were performed with the use of Prism software (version 5.0; GraphPad Software, San Diego, CA).
Cell Culture and Adipocyte Differentiation Assay. Murine 3T3-L1 cells were cultured at 37°C and 5% CO 2 in DMEM, high glucose, and HEPES, pH 7.4, supplemented with 10% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin. Cells were differentiated to adipocytes as described previously (Klemm et al., 2001) . In brief, postconfluent 3T3-L1 cells were maintained in DMEM/Ham's F-12 medium supplemented with 10% FBS, 1 M dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, 167 nM insulin, and 1 M rosiglitazone for 3 days. The effect of luteolin on rosiglitazone-induced differentiation was assessed by adding 5, 10, or 20 M luteolin during this period. After 3 days, cells were maintained in DMEM/ Ham's F-12 supplemented with FBS, insulin, and dexamethasone until harvesting. On day 8 of differentiation, cells were stained with Oil Red O to estimate in vitro adipogenesis as described previously (Klemm et al., 2001) . For gene expression analysis, on day 8 of differentiation, cells were treated as follows: 1) control (no treatment); 2) 10 M luteolin; 3) 20 M luteolin; 4) 1 M rosiglitazone; and 5) 20 M luteolin and 1 M rosiglitazone. After 24 h, total RNA was extracted.
Quantitative Real-Time Reverse Transcription-PCR. Total RNA was extracted on day 8 of 3T3-L1 cell differentiation using Aurum Total RNA Fatty and Fibrous kit (Bio-Rad Laboratories, Hercules, CA), in accordance with the manufacturer's instructions. A PPAR␥ Activation by Luteolin 789 at ASPET Journals on November 7, 2017 molpharm.aspetjournals.org total of 160 ng of total RNA was reverse-transcribed using random hexamers and SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen). Real-time quantitative PCR analysis was performed using SYBR Green PCR Master Mix (Roche), and the following gene specific primers were used: ␤-actin: forward, 5Ј-GTGACGT-TGACATCCGTAAAGA; reverse, 5Ј-GCCGGACTCATCGTACTCC; CEBPa: forward, 5Ј-GCGGGAACGCAACAACATC; reverse, 5Ј-GT-CACTGGTCAACTCCAGCAC; LPL: forward, 5Ј-GCTGGGCCTA-ACTTTGAGTATG; reverse, 5Ј-AAATCAGCGTCATCAGGAGAA; and OLR1: forward, 5Ј-CTGCACTCCTTCTTCCCTTT; reverse, 5-ЈGCCTG-CACTTGAGGAGGATTT. For analysis of GLUT4 expression, TaqMan real-time PCR was performed using LightCycler 480 Probes Master Mix (Roche) and primers supplied by Applied Biosystems (Foster City, CA). The relative expression of mRNA was determined by normalization to ␤-actin levels using the ⌬⌬C t method. The results were considered to be significant at p values less than 0.05, as measured by Student's t test (paired data).
PPAR␥ Expression and Purification. The plasmid pET28a(ϩ) (Novagen, Madison, WI) encoding a human PPAR␥ LBD fused in frame to the C terminus of a polyhistidine (His) tag was used to transform competent Escherichia coli strain BL21 (DE3). An initial culture was then inoculated at 1% in a major Luria broth culture and grown at 37°C until OD 600 nm reached 0.8. After this, protein expression was induced with 1 mM isopropyl ␤-D-thiogalactoside for 16 h at 18°C. Cells were harvested by centrifugation, and the cell pellet was resuspended in 20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol and incubated on ice with 0.5 mg/ml of lysozyme for 30 min. The cells were disrupted by sonication, and cell debris was removed by centrifugation. The His-tag PPAR␥ LBD was purified by metal-affinity chromatography from the supernatant using a Talon Superflow Metal Affinity Resin (Clontech, Mountain View, CA). The protein was eluted with stepwise incubations, the lysis buffer containing 100 and 300 mM imidazole, and eluted fractions were pooled and subjected to size-exclusion chromatography (AKTA Purifier System; AKTA Basic; GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK), using Superdex 75 16/60 (GE Healthcare) previously washed and equilibrated with 20 mM TRIS-HCl buffer, pH 8.0, containing 1 mM dithiothreitol, 100 mM NaCl, and 5% glycerol. Samples containing the PPAR␥ LBD were processed to a final concentration of 10 mg/ml and stored at Ϫ80°C. The His-tag was removed by digestion with bovine thrombin (Sigma-Aldrich, St. Louis, MO). The protein content and purity of all chromatographic fractions were analyzed by Coomassie Blue-stained SDS/polyacrylamide gel electrophoresis. Protein concentrations were determined using the Bradford dye assay (Bio-Rad Laboratories) using bovine serum albumin as standard.
Crystallization, Data Collection, and Structure Determination. PPAR␥ LBD at 10 mg/ml was mixed with 1 mM luteolin on ice and allowed to stand at 4°C overnight. The crystallization screens were preformed under conditions similar to those described previously (Nolte et al., 1998) , using hanging drop of 1 l of protein complex solution mixed with 1 l of precipitant solution and equilibrated against a 500 ml of reservoir solution containing 100 mM HEPES, pH 7.0 to 8.0, 0.75 to 1.3 M sodium citrate. Suitable crystals were obtained within 2 to 3 days with 100 mM HEPES, pH 7.0, and 0.85 M sodium citrate. Before data collection, the crystals were soaked in a cryoprotectant containing the same reservoir solution added with 15% (v/v) ethylene glycol and rapidly cooled in a gaseous nitrogen stream at 100 K. X-ray diffraction data were collected in the protein crystallography MX2 beamline at the Laboratório Nacional de Luz Síncroton (LNLS, Campinas, Brazil) (Guimarã es et al., 2009). Diffraction data were processed using MOSLFM (Leslie, 1999) and scaled with SCALA from the CCP4 program suite (Collaborative Computational Project Number 4, 1994) .
The structure was determined by molecular replacement using the program PHASER from CCP4 Packages and the PPAR␥ LBD (PDB code 2PRG) structure as a model. The programs PHENIX and COOT were used to alternately run cycles of refinement and model building (Emsley and Cowtan, 2004; Adams et al., 2010) .
Molecular Dynamics Simulations. For simulations, the missing residues of the crystallographic structure presented in this work (chain B) were completed using coordinates obtained from the chain B of the structure 1PRG (Nolte et al., 1998) of PDB, after structural alignment using the program LovoAlign (Martínez et al., 2007) . Modeled residues received special energy minimization treatments before the production runs (see below). The structure was then fully solvated with a water shell of at least 16 Å, and Na ϩ and Cl Ϫ ions were added at concentration of 0.15 M to render the system electrically neutral. Short-range interactions were truncated at a cut-off radius of 12 Å, and electrostatic interactions were evaluated via the Particle Mesh Ewald (PME) method, using periodic boundary conditions. After this procedure, PPAR␥-luteolin and PPAR␥-rosiglitazone complexes were built using the new structure described here and the chain D of the structure 1FM6 of the PDB (Gampe et al., 2000) , respectively. The final systems contained around 56,000 atoms.
The CHARMM force field (MacKerell et al., 1998 ) was used to model the interactions of both the protein and the fatty acid, and the three-site transferable intermolecular potential (TIP3P) model was used for water (Jorgensen et al., 1983) . Partial charges for luteolin were obtained via ab initio quantum calculation at RHF/6-31G(d) level using the Merz-Kollman charge adjustment scheme (Singh and Kollman, 1984) . Dihedral angle parameters for the torsion around the chemical bond between the two aromatic rings of luteolin were obtained through nonlinear fitting of the quantum potential energy surface obtained at the B3LYP/6-31(d) level, following a protocol similar to that described recently by us (Hansson et al., 2011) . The quantum calculations were performed with Gaussian 03 (Frisch et al., 2004) . All other force-field parameters for luteolin were obtained by analogy with the CHARMM force field. Force-field parameters for rosiglitazone were obtained previously (Hansson et al., 2011) .
Systems were prepared for production runs by 1) 2000 steps of energy minimization using the conjugate gradients algorithm, keeping all atoms of the protein and ligands fixed, except the modeled residues; 2) with the same atoms fixed, 200 ps of molecular dynamics (MD) in the isothermal-isobaric ensemble; 3) 1000 conjugate gradient steps keeping only the C␣ fixed; 4) 200 ps of MD in the isothermal-isobaric ensemble, with C␣ fixed; and 5) 600 ps of MD without any restraint. The productions runs were 3 ns and the temperature and pressure were set to 300 K and 1 atmosphere, respectively. For each system, this protocol was repeated five times to provide adequate statistical sampling. The simulations were performed with the program NAMD (Phillips et al., 2005) .
Enzyme-Linked Immunosorbent Assay. IL-8 release from hypertonic-stressed SV40-immortalized HCECs was measured using an enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN) as described in the manufacturer's instructions. HCECs were cultured in DMEM/Ham's F12 medium supplemented with 10% FBS, 5 ng/ml epidermal growth factor, 5 g/ml insulin, and 40 g/ml gentamicin in a humidified incubator with a 5% CO 2 /95% atmosphere air at 37°C. They were transferred to 12-well culture plates and grown until they reached approximately 80% confluence and then exposed to either a PPAR␥ antagonist [2-chloro-5-nitro-N-4-phenylbenzamide (GW9662; Cayman Chemical, Ann Arbor, MI)] or luteolin (Cayman Chemical) for 30 min before exposing them to NaCl-supplemented hypertonic (450 mOsM) DMEM/Ham's F12 medium for 24 h. Supernatants were harvested after centrifugation at 1000 rpm for 5 min to remove cell debris. The supernatants were stored at Ϫ80°C until analysis. Protein concentration of each cell lysate was determined by using a bicinchoninic acid protein assay kit (Thermo Scientific). The amount of IL-8 in the culture medium was normalized to the total amount of cellular protein lysed with 5% SDS and 0.5 N NaOH. Results are expressed as mean picograms of IL-8 per milligram of cell protein Ϯ S.E.M. Each experiment was performed in triplicate and repeated three times (n ϭ 3). The results 790 were considered to be significant at p values less than 0.05, as measured by Student's t test (paired data).
Transepithelial Electrical Resistance Measurement. For HCEC transepithelial electrical resistance measurements, cells were seeded on Transwell permeable supports having a 24-mm diameter and pore size of 0.4 m and placed in six-well plates (Corning Life Sciences, Acton, MA) at a density of 5 ϫ 10 5 cells per well. They were cultured using DMEM/Ham's F12 medium supplemented with 10% Fig. 1 . Cell transactivation assays. PPAR␥/GAL4 transactivation assay were performed with serial dilutions of different concentrations of luteolin in activation and competition mode, shown as dose-response curve (A) and fold activation of luciferase (B). Both graphs show the activation and competition with 1 M rosiglitazone by addition of luteolin. All assays were performed in three replicates and were normalized for differences in transfections efficiency by measuring R. reniformis luciferase activity in the same lysate. 
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fetal bovine serum (Invitrogen, Carlsbad, CA). The inserts were air-lifted and exposed to 1 ml of medium in the bottom chamber. After approximately 5 days, the cultures reached confluence based on stable transepithelial electrical resistance values. TEER (ohms per square centimeter) was measured with hand-held electrodes connected to a volt-ohm meter (EVOM; World Precision Instruments, Sarasota, FL) and corrected by subtracting the resistance of an empty insert (Yang et al., 2000) .
Results
Luteolin Is a Partial PPAR␥ Agonist. We performed cell transactivation assays to re-evaluate activity of luteolin relative to rosiglitazone. Dose-response curves obtained with seven different luteolin concentrations are shown in Fig. 1A , where each point represents the mean of three replicates performed in triplicate. Luteolin exhibited moderate, partial agonist-like PPAR␥ LBD transactivation activity with an EC 50 of 15.6 M. The maximal activity achieved by luteolin was 35% of that observed for the full PPAR␥ agonist rosiglitazone ( Fig. 1B) . Rosiglitazone response was inhibited by luteolin in a competition assay (Fig. 1B) , with an IC 50 of 21.8 M, consistent with its partial agonist behavior. Luteolin concentrations greater than 50 M were cytotoxic, as indicated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium cell viability assay (data not shown).
Luteolin Regulates PPAR␥ Target Genes in 3T3-L1 Cells and Inhibits Rosiglitazone-Induced Differentiation. We used quantitative real time PCR to determine whether luteolin regulates expression of PPAR␥ target genes in 3T3-L1-differentiated cells. After 8 days of differentiation, quantitative real-time PCR was performed on adipocytes treated Ϯ luteolin (10 and 20 M), rosiglitazone (1 M), or a combination of these ligands (1 M rosiglitazone ϩ 20 M luteolin) for 24 h. As a negative control, we used cells incubated with DMEM instead of standard differentiation medium. As expected, rosiglitazone induced known target genes that regulate fatty acid metabolism and glucose transport such as LPL, ORL1, CEBPa, and GLUT4 (Morrison and Farmer, 1999; Laplante et al., 2003; Chui et al., 2005; Armoni et al., 2007) (Fig. 2) , whereas luteolin actively repressed expression of LPL and OLR1 (Fig. 2, A and B) and did not affect CEBP␣ expression ( Fig. 2C ). However, luteolin did induce GLUT4 similarly to rosiglitazone (Fig. 2D ). Accordingly, rosiglitazone effects on LPL, OLR1, and CEBPa were inhibited by 20 M luteolin, whereas expression of GLUT4 was similar to that in response to rosiglitazone or luteolin alone (Fig. 2) . Thus, luteolin behaves as a weak partial agonist/antagonist at several genes in 3T3-L1 cells but also displays full agonist activities at one gene.
Luteolin also inhibited effects of rosiglitazone on adipocyte differentiation. 3T3-L1 cells were treated with 1 M rosiglitazone in presence of 5, 10, and 20 M luteolin for 3 days after confluence. On day 8 of differentiation, cells were stained with Oil Red O to verify lipid accumulation. As expected, rosiglitazone triggered efficient differentiation to adipocytes (Fig. 3) , and this effect was reversed by luteolin in a dose-dependent manner.
Luteolin and Myristic Acid Simultaneously Bind the PPAR␥ LBD. To understand the molecular basis of luteolin partial agonism/antagonism, we obtained an X-ray cocrystal structure of the PPAR␥ LBD with luteolin at 2.3 Å resolution. The structure, solved in the monoclinic C2 space group, shows good geometric and crystallographic parameters and no residues in the disallowed region of the Ramachandran plot (Table 1 ). In common with previous PPAR␥ LBD structures, the asymmetric unit contains a homodimer of the PPAR␥ LBD, with chain A in the canonical active nuclear receptor conformation and chain B in an inactive conformation caused by crystallographic contacts (Nolte et al., 1998) . The structure of PPAR␥ LBD consists of 12 ␣-helices that form the classic three-layered antiparallel ␣-helical sandwich fold with a small four-stranded ␤-sheet, as described for other PPAR␥ structures (Nolte et al., 1998; Li et al., 2008) .
It is noteworthy that, as opposed to previous studies in which PPAR ligands preferentially bind to the PPAR␥ A chain (active configuration) (Itoh et al., 2008) , luteolin occupied the LBP of PPAR␥ chain B (inactive conformation) ( Fig. 4) . We also detected a second ligand, a long-chain fatty acid simultaneously bound in the chain B LBP, consistent with previous demonstrations that PPAR␥ can accommodate more than one ligand in the LBP (Itoh et al., 2008; Waku et al., 2010) . Because fatty acids were not added during crystallization, we assume that this ligand copurified with the recombinant protein from the bacteria.
Gas chromatography-mass spectrometry analysis of the drops containing the crystals revealed myristic (14:0), palmitic (16:0), and stearic acids (18:0) in the samples (not shown). Myristic acid fits well in the electron density found in chain B. In chain A, electron densities of two fatty acids are also observable but are not as well defined as in chain B. As such, it was only possible to model fatty acids up to nine carbons long in chain A (Fig. 5, C and D) , despite the results of the gas chromatography-mass spectrometry experiment. The fatty acid located at H3 and H5 makes hydrophobic contacts with Glu295, Ala292, Arg288, Ser289, Cys285, Phe226, Met329, Ile326, and Leu330 (Fig. 5C ), whereas the fatty acid located between H3 and ␤-sheet makes hydrophobic interactions with Gly259, Arg280, Ile281, Arg288, Ser342, and Ile341 (Fig. 5D ).
Luteolin Binds PPAR␥ in a Different Binding Mode from TZDs. Unlike the TZDs, which adopt a U-shape configuration in the LBP and wrap around H3 to directly contact the activation function 2 helix (H12), luteolin occupies the region of PPAR␥ delimited by the H3 and the ␤-sheet and makes no contact with H12, which is displaced in the B-chain (Fig. 4) . Despite the fact that luteolin binds in a different mode than rosiglitazone, occupying the region between H3 and ␤-sheets, A and B rings of luteolin clash with rosiglita- Fig. 4 . Structure of PPAR␥ in complex with luteolin and fatty acids. A, luteolin is blue, myristic acid is yellow, and fatty acids modeled with nine carbons are orange. The C␣ atoms of the LBD are magenta (H12), green (␤-sheet), and gray (other region). B, superposition of PPAR␥ in complex with luteolin/myristic acid and PPAR␥ in complex with rosiglitazone (PDB code 2PRG). 2PRG (pale green) structure presents H12 (orange) in active conformation. Rosiglitazone (red) makes hydrogen bonds with Tyr473 of H12. zone when our structure was superposed with that in PDB entry 2PRG (Fig. 4B ). Luteolin makes two hydrogen bonds with the main chain of the residue Lys265 and the side chain of His266, both located at the ⍀-loop that links H2 to H3 and also makes important hydrophobic interactions with Phe264, Gly284, Phe287, Cys285, Arg288, Leu330, Ser342, Ile341, Met364, and Val339 (Fig. 5A ). MD simulations starting from this crystallographic structure showed that the binding mode of luteolin is quite stable, and it exhibits only local fluctuations, with root-mean-square deviation of 0.6 Ϯ 0.2 Å. Moreover, the simulations also revealed that an additional hydrogen bond not evident in the structure could be established between luteolin and residue Glu291 (H3), which could help to anchor luteolin to the ⍀-loop (Fig. 6 ). Myristic acid, in turn, occupies the region of the LBD composed of H3, H5, and H7 and makes a salt bridge with Arg288 (H3), with its aliphatic chain surrounded by the residues Ser289, Cys285, Leu330, Leu333, Met364, Phe363, and His449 (Fig. 5B) .
MD simulations provide further insights into the binding mode. A water molecule bridges luteolin and the carboxylate of the myristic acid through another hydrogen bond (Fig. 6 ) and is relatively stable; it is never exchanged with bulk solvent on the time scale of the simulations and seems to be important for anchoring the luteolin in the LBD. It is noteworthy that simultaneous binding of the two ligands seems to be cooperative, because they interact with energy of Ϫ11 Ϯ 4 kcal/mol, largely of electrostatic origin. Together, the X-ray structural analysis and the MD simulations suggest that the large binding pocket of the PPAR␥ LBD makes the simultaneous binding of luteolin and myristic acid possible and that participation of a structural water molecule is involved in the recognition of these ligands.
Rosiglitazone and Luteolin/Myristic Acid Stabilize Different Regions of the LBD. The fact that the luteolin/ myristic acid combination binds the LBD in a mode different from that of full agonists raises the possibility that receptor dynamics could be differentially affected by the particular ligand binding mode (Kallenberger et al., 2003; Hamuro et al., 2006) . Comparisons of B-factors of our structure, an indication of mobility, and PPAR␥ with rosiglitazone (PDB code 2PRG) demonstrate that these ligands stabilize different regions. It is noteworthy that luteolin stabilizes ⍀-loop, whereas rosiglitazone stabilizes the AF2 helix (Fig. 7A) .
We also used MD to compare effects of luteolin/myristic acid and the full agonist rosiglitazone on LBD dynamics. Both simulations used LBD structures in the active configuration. Consistent with the B-factor analysis, the simulations predict that the entire ␤-sheet region, the ⍀-loop and H2Ј, are preferentially stabilized by luteolin/myristic acid, whereas rosiglitazone preferentially stabilizes H11 and H12 (Fig. 7B) . The rosiglitazone-induced stabilization of H12 is explained by a strong H-bond with residue Tyr473 (H12), which is the structural basis of its agonist behavior (Nolte et al., 1998) . In contrast, we found three reasons for the enhanced ligandinduced stabilization of the ␤-sheet region by luteolin and myristic acid relative to rosiglitazone. First, residue His266 (⍀-loop) is kept rigid as a result of an important H-bond with luteolin and is free to turn to the solvent in the presence of rosiglitazone. In fact, the part of the ⍀-loop that is stabilized by luteolin is not seen in chain A of the structure, where luteolin is absent, consistent with a role in stabilization of ⍀-loop dynamics. Second, residues Ser342 (␤-strand 3) and Lys263 (H2Ј) are hydrogen-bonded throughout almost the entire simulation when the luteolin is bound to the LBD, which also results in the H2Ј/⍀-loop stabilization (Figs. 7, C and D) . In the presence of rosiglitazone, on the contrary, this configuration is never established. Thus, besides binding to and stabilizing the ⍀-loop, luteolin is able to induce the formation of protein-protein interactions in the LBD that contribute to H2Ј/⍀-loop stabilization. Third, luteolin and myristic coordinate binding of two water molecules that are tightly bound to the backbone of the residues Leu340 and Ser342, both located at the ␤-sheet (Fig. 7E) . So, in addition to the hydrophobic contacts between the aromatic rings of luteolin and the side chains of residues of the ␤-sheet, watermediated hydrogen bonds may be important for the stabilization of the ␤-sheet relative to rosiglitazone complex, in which no immobilized water molecules bind to residues of the ␤-sheet. Thus, luteolin adopts a different binding mode from TZDs and selectively stabilize different regions of the LBD.
Luteolin Promotes Decrease in Production of IL-8 after Hypertonic Challenge. Because PPAR␥ overexpression in mice reduced inflammatory and fibrotic responses in corneas subsequent to injury, we used HCECs to assess whether luteolin could suppress injury induced by hypertonic stress, which frequently occurs in dry-eye disease (see Introduction) , and can trigger increases in IL-8 release by resident cells in the corneal epithelium and the underlying stroma (Luo et al., 2005; Li et al., 2006) and reductions in TEER.
We exposed the HCECs to a hypertonic challenge simulating the dry-eye condition and evaluated the effects of luteolin on hypertonic-induced increases in IL-8 release. Figure 8A shows that hypertonic challenge induced a 3.1-fold increase in IL-8 release over 24 h. This rise was obviated by preexposing the cells for 30 min to 5 M luteolin 24 h and partially reversed by exposing the cells to 1 M luteolin. It is noteworthy that IL-8 production was increased by the PPAR␥ antagonist GW9662 under isotonic conditions (Fig.  8B) , and preincubation with luteolin reversed this effect. Thus, individual effects of luteolin and GW9662 on IL-8 release are attributable to their respective partial activation and suppression of PPAR␥ activity.
Finally, we determined whether luteolin modulates the decline in TEER induced by a hypertonic stress. We measured effects on TEER at 375 mOsM because decline of the TEER was not reversible upon restoration of isotonic medium at higher osmolarities (not shown). Figure 9 shows that under the isotonic condition, TEER declined slightly at 5 h, and this effect was reversed completely at 15 h. On the other hand, with the 375 mOsM medium, TEER also fell initially after 5 h without full restoration at 20 h. Pre-exposure to luteolin fully prevented the decline in TEER at 5 h, and the protective effect was also evident at 9 and 20 h.
Discussion
In this work, we investigated the mode of action of luteolin in activating PPAR␥ by performing functional studies, X-ray crystallography analysis, and molecular dynamics simulations. We found that luteolin exhibits weak partial agonist behavior relative to the full agonist rosiglitazone in cell transactivation assays and that it acts predominantly as an antagonist in gene expression and adipocyte differentiation assays, explaining apparently contradictory results that have suggested that this ligand is an agonist or an antagonist (Mueller et al., 2008; Park et al., 2009; Ding et al., 2010) . Our studies also revealed that luteolin exhibits full agonist actions at least one gene in 3T3-L1 cells, GLUT4, and acts as a potent anti-inflammatory agent through PPAR␥ in HCECs. Thus, luteolin also exhibits interesting selective PPAR␥ modulator actions.
The crystallographic structure is consistent with the idea that luteolin is a weak partial agonist with antagonist actions and also suggests similarities between binding modes of luteolin and other SPPAR␥Ms. Luteolin preferentially binds the nominally inactive B-chain subunit of the PPAR␥ crystallographic dimer. This is distinct from other PPAR␥ ligands with full agonist character or partial agonists, which either bind exclusively to the A-chain or occupy both subunits, but are well defined in the A-chain LBP and poorly resolved in the context of the B-chain (Itoh et al., 2008) . Second, luteolin is far from H12; this, coupled with B-factor measurements and MD simulations, which indicate that H12 is poorly tethered, suggest that H12 will be highly dynamic and able to adopt active and inactive conformations in the presence of Another hydrogen bond with Glu291, not evident from the X-ray data, is formed during the dynamics, which could help in the stabilization of the luteolin interactions. In addition, a water-mediated hydrogen bond between the luteolin and the myristic acid is shown. This water molecule never exchanges with the bulk solvent and seems to be structurally important for the particular binding mode of luteolin.
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luteolin. Luteolin also binds close to, and strongly stabilizes, the H3/␤-sheet region of the LBD (Fig. 4) , similar to PPAR␥ partial agonists, which act as preferential insulin sensitizers (Bruning et al., 2007) , inhibit cyclin-dependent kinase 5-dependent phosphorylation, and exhibit insulin-sensitizing effects without harmful side effects in animal models (Choi et al., 2010; Choi et al., 2011) . Luteolin has documented beneficial effects on blood glucose and insulin sensitivity, similar to SPPAR␥Ms Acton et al., 2005; and inhibits PPAR␥ adipogenic activity (Park et al., 2009 ) while potentiating insulin action in adipocytes (Ding et al., 2010) and endothelium (Deqiu et al., 2011) . It is therefore interesting to suggest that desirable properties may relate to the binding position of luteolin in the LBP.
Our structure reveals myristic acid, probably bacterial in origin, in the LBP along with luteolin. Previous studies have shown that the PPAR␥ LBP can accommodate more than one ligand (Waku et al., 2010) . Although this raises the possibility that PPAR␥ may sense a phytochemical and a fatty acid (or, perhaps, other combinations of signaling molecules), we have not been able to obtain any evidence that myristic acid alters luteolin activities through PPAR␥ in transfections (not shown). However, our MD simulations do suggest that luteolin and myristic acid cooperate to stabilize the ⍀-loop, which links H2Ј to H3, explaining why it is visible in our structure even though it is often impossible to resolve, irrespective of ligand type. Furthermore, comparison of B-factors in the presence of luteolin/myristic acid and rosiglitazone (PDB code 2PRG) indicates that luteolin preferentially stabilizes ⍀-loop and ␤-sheet (Fig. 7A) , whereas rosiglitazone preferentially stabilizes H12 (Fig. 7B ) because of a strong H-bond with the residue Tyr473 (H12) (Fig. 4B) (Nolte et al., 1998) . MD simulations indicate that luteolin and myristic acid are both involved in the preferential stabilization of the entire ␤-sheet region of the LBD, including ⍀-loop and H2Ј. This is related to a strong H-bond with His266 (⍀-loop), which is free to turn to solvent in the presence of rosiglitazone; residues Ser342 (␤-strand 3) and Lys263 (H2Ј) remain hydrogen- Fig. 7 . Ligand-induced stabilization of ⍀-loop/␤-sheet region. A, B-factors of PPAR␥_LBD in complex with rosiglitazone (PDB code 2PRG) and with luteolin/myristic acid. The thickness of the schematic representation is directly proportional to the temperature factors of the region. In the structure with rosiglitazone, the H12 is the active state, and in the structure of luteolin/myristic acid, it is in an inactive state as a result of crystallographic contacts. Luteolin (magenta), myristic acid (gray), and rosiglitazone (brown) are shown as sticks. B, the LBD structure colored according to the mobility as measured by the average root-mean-square deviation of the ␣ carbons. The blue regions are those that are more stabilized by luteolin/myristic acid than by rosiglitazone; the red regions are those stabilized by rosiglitazone relative to luteolin/myristic acid. The ␤-sheet region is more stabilized by luteolin, whereas rosiglitazone, being a full agonist, preferentially stabilizes H11 and H12. C, a snapshot of the simulations of PPAR␥ bound to luteolin (orange) and to rosiglitazone (green) showing the spatial configurations of the residues Lys263 and Ser342, which are kept in contact in the presence of luteolin, contributing to the stabilization of the H2Ј and ⍀-loop region. D, the distributions of the distance between the residues Lys263 and Ser342 in the presence of luteolin and rosiglitazone, showing the differences between the ligand-induced effects on this region. E, the H-bond network involving luteolin, myristic acid, Leu340, Ser342, and two water molecules. These water molecules bind the two ligands to the ␤-sheet and are never seen exchanging with the bulk solvent during the course of the simulations.
bonded throughout almost the whole simulation time; and luteolin and myristic acid have the ability to coordinate two molecules of water tightly bound to the backbone of residues Leu340 and Ser342, both located at the ␤-sheet (Fig. 7E) . The aromatic rings of luteolin also make hydrophobic interactions on the ␤-sheet, at residues such as Val339, Ile341, and Ser342, and MD simulations also reveal a water-mediated hydrogen bond with Ser342.
The significance of ⍀-loop stabilization is not clear. There are precedents for ligand interaction with the ⍀-loop; ajulemic acid, a synthetic cannabinoid that lacks hallucinogenic activities and is a partial PPAR␥ agonist also makes polar contacts with the main chain of Lys265 and His266 and extensive hydrophobic contacts with the side chain of Phe264 (Ambrosio et al., 2007) . Previous studies suggested that fatty acid metabolites activate PPAR␥ through structural rearrangements of the ⍀-loop and that distinct degrees of the receptor activities in cells are derived from structural differences in this region (Waku et al., 2009 ). Because luteolin also seems particularly ineffective at stabilizing H12, it is inter-esting to suggest that its weak partial agonist and genespecific agonist actions may derive from a mechanism distinct from full agonists and that the ␤-sheets and ⍀-loop participate in these effects (Bruning et al., 2007) .
Finally, even though luteolin is a weak partial agonist, it exhibits strong anti-inflammatory potential in the corneal epithelial and endothelial layers, and this suggests that it may have therapeutic value in ocular diseases (Sarayba et al., 2005) . Flavonoids are known to exhibit anti-inflammatory activities (Havsteen, 2002) , and we have shown here that luteolin reverts the hypertonic-induced increase in IL-8 in HCECs through PPAR␥, as indicated by the ability of luteolin to reverse decreased IL-8 production induced by PPAR␥ antagonist GW9662. Luteolin can also provide a protective effect against declines in TEER induced by exposure to 375 mOsM medium. We cannot yet explain anti-inflammatory actions in terms of effects on PPAR␥ structure and dynamics, but our structure does suggest that anti-inflammatory actions must be independent of full H12 stabilization. Thus, protective effects rendered against hypertonic induced Fig. 8 . A, luteolin reverses hypertonic-induced increases in IL-8 release: HCECs were cultured in multiwell plates for 24 h in the presence and absence of 5 M luteolin. When luteolin was used, the cells were pre-exposed to this PPAR␥ agonist luteolin for 30 min before substituting the isotonic (i.e., 300 mOsM) medium with a 450 mOsM hypertonic counterpart. ELISA was used to measure IL-8 release into the medium. Each experiment was performed three times in triplicate ‫,ء(‬ significant under isotonic conditions between values in the presence and absence of luteolin; ‫,ءء‬ significant under hypertonic conditions between values in the presence and absence of luteolin. ‫,ء‬ ‫,ءء‬ P Ͻ 0.05, values are expressed as mean Ϯ S.E.M.). B, luteolin reverses GW9662-induced increases in IL-8 release: HCECs were cultured in multiwell plates and pre-exposed to 1 M GW9662 for 30 min before adding 1 or 5 M luteolin in isotonic medium. ELISA measured IL-8 release into the medium. Each experiment was performed three times in triplicate ‫,ء(‬ in isotonic medium, significant between values in the presence and absence of luteolin; ‫,ءء‬ significant between values obtained with GW9662 alone relative to those obtained after exposure to both luteolin and GW9662. (P Ͻ 0.05, values are expressed as meanϮ S.E.M.). Fig. 9 . Luteolin reduces hypertonic-induced TEER declines. HCECs were cultured in transwell plates and incubated in 1 or 5 M luteolin for 30 min, and then were exposed to either 375 mOsM medium or isotonic medium for 20 h. TEER was measured at the indicated times. Data are shown as means Ϯ S.E.M. of triplicate measurements from three different experiments for each condition. Either 1 or 5 M luteolin fully protected HCECs from declines in TEER induced by exposure to 375 mOsM medium. ‫,ء‬ P Ͻ 0.05, versus the corresponding value for cells incubated with isotonic medium.
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at ASPET Journals on November 7, 2017 molpharm.aspetjournals.org Downloaded from increases in IL-8 release by HCECs and accompanying declines in epithelial barrier function by luteolin suggest that a weak partial PPAR␥ agonist, with possibly a safer profile than full PPAR␥ agonists, will exhibit useful effects in eye disease and injury-induced inflammation. In summary, PPAR␥ may be a novel therapeutic target for treating dry-eye patients, and the fact that luteolin, with a unique binding mode and activity profile relative to TZDs, exhibits efficacy in this system suggests that it should be possible to elicit such actions with safe partial agonists or SPPARM␥ ligands that lack full agonist activity.
